[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"conditionNormalized\":\"hepatitis-c-virus-chronic-infection\",\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:hepatitis-c-virus-chronic-infection":68},{"pageToken":4,"total":5,"offset":6,"count":5,"results":7},null,3,0,[8,52,86],{"id":9,"slug":10,"hasResults":11,"nctId":12,"briefTitle":13,"officialTitle":14,"acronym":15,"eligibilityCriteria":16,"healthyVolunteers":11,"sex":17,"minAge":18,"maxAge":19,"enrollmentInfo":20,"targetDuration":4,"studyType":23,"phases":24,"briefSummary":26,"conditions":27,"keywords":30,"overallStatus":39,"whyStopped":4,"lastUpdateSubmitDate":40,"lastUpdatePostDateStruct":41,"startDateStruct":44,"completionDateStruct":46,"leadSponsor":48,"locationsCount":51},"100630434","evaluation-of-the-hepatoprotective-effects-of-a-nutritional-supplement-in-patients-with-liver-disease-secondary-to-chronic-hepatitis-c-virus-infection-resqueti-study-100630434",false,"NCT07487623","Evaluation of the Hepatoprotective Effects of a Nutritional Supplement in Patients With Liver Disease Secondary to Chronic Hepatitis C Virus Infection (RESQUETI Study).","Evaluation of the Hepatoprotective Effects of a Nutritional Supplement Containing Resveratrol, Quercetin, Taurine, Inulin, and Whey Protein on Biochemical, Molecular, and Clinical Markers in Patients With Liver Disease Secondary to Chronic Hepatitis C Virus Infection (RESQUETI Study).","RESQUETI","Inclusion Criteria:\n\nPatients with liver disease secondary to chronic hepatitis C virus infection who attend the outpatient Hepatitis Clinic of the Gastroenterology Department at Hospital Civil Fray Antonio Alcalde.\n\nChild-Pugh score \\\u003C 8 points. Age 18-69 years. Both sexes. Signed informed consent.\n\n\\-\n\nExclusion Criteria:\n\n* Patients with alcohol consumption within the past 6 months. Patients with a history of acute-on-chronic liver failure (ACLF). Patients with persistent hepatic encephalopathy. Patients unable to perform frailty assessments. Patients with refractory ascites. Patients with a history of hepatorenal syndrome. Patients with a history of hepatopulmonary syndrome. Patients with chronic kidney disease. Patients with autoimmune diseases. Patients with any type of cancer. Patients with dementia or other significant mental illnesses. Use of protein supplements or probiotics.","ALL","18 Years","69 Years",{"count":21,"type":22},26,"ESTIMATED","INTERVENTIONAL",[25],"NA","The purpose of this clinical trial is to evaluate whether a nutritional supplement containing resveratrol, quercetin, taurine, inulin, and whey protein improves biochemical and molecular markers, as well as clinical outcomes, in patients with liver disease related to chronic hepatitis C infection.\n\nThe study will compare the investigational supplement with an active control (whey protein alone) to determine whether the combination formulation provides additional benefits on liver-related biomarkers and clinical assessment.\n\nParticipants will:\n\nTake the investigational supplement or active control daily for 12 weeks.\n\nAttend clinic visits every 4 weeks for laboratory testing and clinical evaluations.",[28,29],"Liver Disease Chronic","HEPATITIS C VIRUS CHRONIC INFECTION",[31,32,33,34,35,36,37,38],"liver disease chronic","hcv","resveratrol","quercetin","taurine","inulin","frailty","whey protein","RECRUITING","2026-03-17",{"date":42,"type":43},"2026-03-23","ACTUAL",{"date":45,"type":43},"2025-10-11",{"date":47,"type":22},"2026-05-15",{"name":49,"class":50},"University of Guadalajara","OTHER",2,{"id":53,"slug":54,"hasResults":11,"nctId":55,"briefTitle":56,"officialTitle":57,"acronym":58,"eligibilityCriteria":59,"healthyVolunteers":11,"sex":17,"minAge":18,"maxAge":4,"enrollmentInfo":60,"targetDuration":62,"studyType":63,"phases":4,"briefSummary":64,"conditions":65,"keywords":67,"overallStatus":39,"whyStopped":4,"lastUpdateSubmitDate":76,"lastUpdatePostDateStruct":77,"startDateStruct":79,"completionDateStruct":81,"leadSponsor":83,"locationsCount":85},"100600261","scaling-up-point-of-care-hepatitis-c-testing-and-treatment-in-canada-100600261","NCT07095192","Scaling Up Point-of-Care Hepatitis C Testing and Treatment in Canada","Scaling Up Point-of-Care Hepatitis C Testing and Treatment in Canada: A Multilevel Implementation Science Study of Clinical Processes, Barriers, Facilitators and Implementation Strategies","SCALE POCT","Inclusion Criteria:\n\n* Individuals aged ≥18 years who have a risk factor for HCV acquisition or are attending a site that provides services to people with an HCV acquisition risk.\n* Service providers and managers who are currently employed at a site providing HCV-related services, involved in or supervising the delivery of HCV-related services.\n* Policymaker must hold a position in local, provincial, or national government or a health authority that influences HCV testing\u002Ftreatment policies and be able to provide insights into the strategic planning and funding for HCV care.\n* Laboratory and quality assurance stakeholders must hold a role in laboratory services, quality assurance, or regulatory oversight of point-of-care testing at the provincial, national, or organizational level.\n\nExclusion Criteria:\n\n* Younger than 18 years old",{"count":61,"type":22},300,"1 Month","OBSERVATIONAL","The SCALE-POCT study is a national initiative designed to provide robust evidence for scaling up point-of-care hepatitis C testing for key populations. The study seeks to map current hepatitis C clinical processes, identify barriers and facilitators to implementation, and co-design practical tools and strategies in partnership with stakeholders.\n\nA major obstacle to hepatitis C elimination and increasing treatment uptake is the current multi-step diagnostic process, which leads to loss to follow-up and treatment delays, particularly among high-risk groups such as people who inject drugs. Point of-care hepatitis C antibody tests (results: 5-20 mins) and RNA tests (results: 60 mins), could enable single-visit diagnosis, reducing loss to follow-up. However, integrating these tests into key settings presents challenges. The overarching goal of this study is to generate evidence to inform the scale-up point-of-care hepatitis C testing and treatment in key settings in Canada. This study is observational in nature and does not involve the direct implementation of point-of-care hepatitis C testing. Instead, it aims to understand the contextual, procedural, and operational factors that would support its successful adoption and sustainability. By examining existing care models and engaging with key stakeholders, the study seeks to build a foundation for future implementation efforts. Specific objectives include:\n\n1. Map current hepatitis C care processes and explore how point-of-care testing could fit into these models;\n2. Identify barriers and facilitators to implementing point-of-care hepatitis C testing across settings and provinces;\n3. Co-design tools and strategies (such as training guides, standard procedures) to support point-of-care testing;\n4. Assess feasibility, acceptability, and costs of the co-designed tools and strategies.",[66,29],"HCV",[66,68,69,70,71,72,73,74,75],"Hepatitis C Virus Chronic Infection","Rapid point-of-care testing","Implementation science","Knowledge translation","Marginalized populations","Infectious diseases","Barriers and facilitators","Implementation strategies","2025-07-23",{"date":78,"type":43},"2025-07-31",{"date":80,"type":43},"2025-05-20",{"date":82,"type":22},"2028-09-20",{"name":84,"class":50},"McGill University",12,{"id":87,"slug":88,"hasResults":11,"nctId":89,"briefTitle":90,"officialTitle":91,"acronym":4,"eligibilityCriteria":92,"healthyVolunteers":11,"sex":17,"minAge":18,"maxAge":4,"enrollmentInfo":93,"targetDuration":4,"studyType":63,"phases":4,"briefSummary":95,"conditions":96,"keywords":4,"overallStatus":98,"whyStopped":4,"lastUpdateSubmitDate":99,"lastUpdatePostDateStruct":100,"startDateStruct":102,"completionDateStruct":104,"leadSponsor":106,"locationsCount":4},"100561903","hepatitis-inequalities-study-100561903","NCT06596213","Hepatitis Inequalities Study","Overcoming Inequalities in Health to Eliminate Hepatitis - Real-World Evidence from a Territory-Wide Cohort","Inclusion Criteria:\n\n* Patients will be eligible if they have any of these viral markers (HBeAg \u002F HBsAg \u002F HBV DNA \u002F HCV RNA) and\u002For any of the following diagnosis codes (ICD-9 070-070.9; 348.3, 349.82, 456, 456.2, 456.8, 567.2, 567.8, 570, 571.2, 571.5, 571.6, 572.2, 572.3, 572.4, 789.5) checked or coded in any public hospitals or clinics from 1 January 2000 to 31 March 2024.\n\nExclusion Criteria:\n\n* Patients with missing age, gender, ethnicity and socioeconomic status\n* (Subgroup analysis for ethnicity and socioeconomic status) Patients with missing ethnicity and socioeconomic status\n* Serious medical illnesses or malignancy with life expectancy \\<1 year",{"count":94,"type":22},100000,"Health inequality in liver diseases including age, gender, ethnicity and socioeconomic status has been increasingly recognised and potentially hinder hepatitis elimination. Health inequality has significant impact to evaluate the impact diagnostic and treatment uptake rates of chronic viral hepatitis on risk of hepatocellular carcinoma (HCC), hepatic event and liver-related death in patients with chronic hepatitis B and\u002For C. To overcome the limitation of small prospective cohort study of limited recruitment period, retrieving information from the Clinical Data Analysis and Reporting System (CDARS) from Hospital Authority (HA) will be one of the best way to answer these questions.",[97,29],"Chronic Hepatitis B","NOT_YET_RECRUITING","2024-09-16",{"date":101,"type":43},"2024-09-19",{"date":103,"type":22},"2024-10-01",{"date":105,"type":22},"2031-06-30",{"name":107,"class":50},"Chinese University of Hong Kong"]